Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Retatrutide

GZBF

Eli Lilly · Phase 2 · Recruiting · Enrollment 300

NCT07467447

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Retatrutide (LY3437943) 1 mg once weekly (no escalation)n/rn/rn/rn/r
Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.n/rn/rn/rn/r
Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).n/rn/rn/rn/r
Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mgn/rn/rn/rn/r
Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.n/rn/rn/rn/r
Placebo once weekly (matched escalation schedule to maintain blinding).n/rn/rn/rn/r
Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.n/rn/rn/rn/r

Not shown

  • Retatrutide (LY3437943) 1 mg once weekly (no escalation): endpoint not reported
  • Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.: endpoint not reported
  • Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).: endpoint not reported
  • Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg: endpoint not reported
  • Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.: endpoint not reported
  • Placebo once weekly (matched escalation schedule to maintain blinding).: endpoint not reported
  • Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.: endpoint not reported